Taylor Thompson

Dr. Thompson is a California native who joined the Department of Medicine and the Pulmonary and Critical Care Unit at MGH in 1985. He directed the Pulmonary and Critical Care Fellowship training program until 1990 and the Medical Intensive Care Unit until 2011. He now the Director of Critical Care Translational Research in the Pulmonary and Critical Care Unit.  His current patient care activities are focused solely on caring for critically ill patients and their families. He has been actively involved in teaching at Harvard Medical School where he is a Professor of Medicine. He has been an active clinical investigator for over 25 years. His primary research and academic interests involve managing clinical trials for patients with the Acute Respiratory Distress Syndrome (ARDS) or severe sepsis, investigating the molecular epidemiology of ARDS and sepsis, and developing and testing computerized bedside decision support tools.

Dr. Thompson is the Medical Director of the NHLBI-funded Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Coordinating Center where he coordinates randomized controlled trials for critically ill patients. In collaboration with Drs’ Christiani and Bajwa at MGH, Dr. Thompson is exploring the molecular epidemiology of ARDS susceptibility and ARDS and sepsis clinical outcomes. Dr Thompson is working with Dr. Michael Matthay at UCSF on the design and implementation of a Phase II trial of mesenchymal stem cells for the treatment of ALI and with Augustine Choi at the Brigham and Women’s Hospital on the design and implementation of a clinical trial of inhaled carbon monoxide as a potential therapeutic agent for ARDS.

Mark Vangel Headshot

Mark Vangel, PhD

Mark Vangel is an Assistant Professor of Radiology at Harvard Medical School and an Assistant Investigator at MGH Biostatistics and the Martinos Center for Biomedical Imaging at MGH. He is also affiliated with the Ferenc Jolesz National Center for Image Guided Therapy at Brigham and Women’s Hospital and the Clinical Research Center at MIT.

His research interests include heteroscadasticity in meta-analysis and mixed-model regression, measurement uncertainty, statistical applications in functional MRI and diagnostic imaging, and Bayesian applications.

Dr. Vangel earned a PhD in Statistics from Harvard University, and SM and SB degrees in Mathematics from MIT.

Jianing Wang, PhD

Jianing Wang is an Assistant Investigator at MGH Biostatistics. Her methodological research centers around advancing indirect methods for hidden population size estimation and spatial and hierarchical modeling approaches for disease characterization and population dynamic prediction. In addition to her extensive collaborative experience in HIV, Hep C, and substance use disorder outcome research, she has been developing an innovative statistical framework for knowledge transfer between large-scale health surveillance systems, as well as the approaches pertinent to neurological disease investigations. Currently, she is involved in projects including HEALEY ALS platform trials, the NIH HEAL Initiative, and the development of a novel community-based high-performance surveillance network for substance misuse.

Dr. Wang completed her PhD in Biostatistics from the Boston University School of Public Health and her MS in Applied Statistics from Boston University.

Beow Yeap

Beow Yeap, ScD

Beow Yeap has collaborated closely with investigators in radiation oncology, radiation physics, medical oncology, molecular pathology, and thoracic surgery at the MGH Cancer Center and Dana-Farber/Harvard Cancer Center since joining MGH Biostatistics in 1999. She has developed extensive experience and expertise in design and analysis of clinical trials and correlative studies for adult and pediatric tumors, with primary focus on proton radiation therapy and molecularly targeted therapies.

Her contributions to translational research encompass preclinical models as well as human studies, including the identification and validation of biomarkers for prognosis and prediction of therapeutic benefit. She has played a leadership role in multi-disciplinary, multi-institutional research efforts as Director of the Biostatistics Core for the Program Project in proton therapy research and DF/HCC SPORE in Lung Cancer.

She has played a leadership role in multi-disciplinary, multi-institutional research efforts as Director of the Biostatistics Core for the Program Project in proton therapy research and DF/HCC Lung Cancer Specialized Program of Research Excellence (SPORE). 

In between her degree studies for an A.M. in Statistics from the Harvard Graduate School of Arts & Sciences and an Sc.D. in Biostatistics from the Harvard T.H. Chan School of Public Health, she gained valuable experience in cancer clinical trials at the Dana-Farber Cancer Institute.